Omeros Corp
NASDAQ:OMER
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Omeros Corp
NASDAQ:OMER
|
US |
|
Talgo SA
F:XTG
|
ES |
|
M
|
Mfe-Mediaforeurope NV
MIL:MFEA
|
IT |
|
E
|
Enagas SA
DUS:EG4
|
ES |
|
C
|
CVS Health Corp
F:CVS
|
US |
|
F
|
Frontdoor Inc
F:3I5
|
US |
Intrinsic Value
Is OMER undervalued or overvalued?
See the intrinsic value estimate for Omeros Corp and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
OMER looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with OMER’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Omeros Does
Omeros Corp is a biotechnology company that develops medicines for serious diseases, especially disorders tied to inflammation, the complement system, and the brain and nervous system. Its work is centered on creating drug candidates in-house, testing them in clinical studies, and moving the most promising ones toward regulatory approval. The company does not sell a broad range of consumer products; it is a drug developer.
- Headquarters
- United States of America US
- Employees
- 175
- IPO date
- Oct 8, 2009
Omeros has no economic moat
Omeros Corp lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysis
Revenue & Expenses Breakdown
Omeros Corp
Earnings Waterfall
Omeros Corp
The intrinsic value for Omeros Corp (OMER) under the Base Case is hidden USD.
Compared with the current market price of 16.86 USD, the stock appears hidden.